We are tempted to hypothesize that the observed trend may, perhaps, be a result of HER2+ patients receiving both anti-HER2 therapy and chemotherapy for treatment of HER2+ breast carcinoma but, due to the small number of these patients in our study population, this effect did not reach a statistical impact. Here, ERBB2 is linked to breast carcinoma.